Redx Pharma
‘004 mono insufficient in BTC; H223 combo is keyRedx Pharma
Recommended all share combination with JounceRedx Pharma
RXC007 recruitment scales up; data now Q124Redx Pharma
Key Phase II data for lead assets expected during H223Redx Pharma
Laying the foundations for further delivery in 2023Redx Pharma
New data draws attention to promising fibrosis assetsRedx Pharma
All the ingredients for success now in placeRedx Pharma
Jazz Pharmaceuticals $5m milestone triggeredRedx Pharma
£34.3m raise extends runway through key data pointsRedx Pharma
RXC008 nominated as GI-ROCK drug candidate